Tumor-derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Exosomes carrying programmed cell death ligand-1 (PD-L1) promote immune suppression, hindering anti-PD-1 cancer therapy. Targeting exosomal PD-L1 offers a new strategy for effective cancer treatment and diagnosis.
Area Of Science
- Immunology
- Oncology
- Cell Biology
Background
- Exosomes mediate intercellular communication and are implicated in cancer progression.
- Programmed cell death ligand-1 (PD-L1) on exosomes can suppress anti-tumor immunity.
- Exosomal PD-L1 contributes to immune evasion and resistance to anti-PD-1 therapy.
Purpose Of The Study
- To review the role of exosomal PD-L1 in immune oncology.
- To highlight exosomal PD-L1 as a biomarker for cancer diagnosis and therapy.
- To discuss exosomal PD-L1 inhibitors as a therapeutic strategy.
Main Methods
- Literature review of studies on exosomes and PD-L1.
- Analysis of exosomal PD-L1's mechanism in T cell suppression.
- Evaluation of exosomal PD-L1 as a biomarker and therapeutic target.
Main Results
- Exosomal PD-L1 targets CD8+ T cells, inducing apoptosis and inhibiting immune responses.
- Tumor cells utilize exosomal PD-L1 to evade immune surveillance.
- Quantification of exosomal PD-L1 shows potential as a diagnostic and prognostic indicator.
Conclusions
- Exosomal PD-L1 plays a critical role in systemic immunosuppression and therapy resistance.
- Targeting exosomal PD-L1 presents a promising therapeutic avenue for cancer treatment.
- Exosomes expressing PD-L1 are valuable biomarkers for lung cancer and immunotherapy efficacy.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...